AlphaMedix is under clinical development by Orano Med and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData, Phase II drugs for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AlphaMedix’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AlphaMedix overview
AlphaMedix is under development for the treatment of gastroenteropancreatic neuroendocrine tumors. The drug is a somatostatin peptide analog which is conjugated to lead-212 (212 Pb). It is administered through the intravenous route. It acts by targeting cells expressing somatostatin receptor 2. The therapeutic candidate is developed based on targeted alpha therapy (TAT) approach. It is a radioligand therapy.
Orano Med overview
Orano Med a subsidiary of Orano SA, is a company that focuses on the development of targeted therapies against cancer. The company’s pipeline products include AlphaMedix which treats neuroendocrine tumors; 212Pb-GRPR for Solid tumors (breast and prostate cancer); 212Pb-PSMA treats prostate cancer; 212Pb PRIT for solid tumors; 212Pb – DARPin-DLL3 / MP0712 which treats small-cell lung cancer; 212Pb DARPin, 212Pb PRRT and 212Pb TAT. It collaborates with partners to develop next-generation radioligand medicines. Orano Med is headquartered in Houston, Texas, the US.
For a complete picture of AlphaMedix’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
